Minor histocompatibility (H) antigens are key molecules driving allo‐immune responses in
both graft‐versus‐host‐disease (GvHD) and in graft‐versus‐leukemia (GvL) reactivity in …

Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for hematological
malignancies. Unfortunately, the desired anti-tumor or graft-versus-leukemia (GvL) effect is …

Minor histocompatibility (H) antigens are major targets of a graft‐versus‐leukemia (GVL)
effect mediated by donor CD8+ and CD4+ T cells following allogeneic hematopoietic cell …

Ever since the discovery of the major histocompatibility complex, scientific and clinical
understanding in the field of transplantation has been advanced through genetic and …

Minor histocompatibility antigens (mHAgs) in allogeneic hematopoietic stem cell
transplantation are highly immunogenic as they are foreign antigens and cause …

Minor Histocompatibility (H) antigens are major histocompatibility complex (MHC)/Human
Leukocyte Antigen (HLA)-bound peptides that differ between allogeneic hematopoietic stem …

Patients with malignant diseases can be effectively treated with allogeneic hematopoietic
stem cell transplantation (allo-SCT). Polymorphic peptides presented in HLA molecules, the …

In the current era of T cell–based immunotherapies, it is crucial to understand which types of
MHC-presented T cell antigens are produced by tumor cells. In addition to linear peptide …

Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological
malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells …

Potent graft-versus-leukemia (GVL) effects can be mediated by donor-derived T cells
recognizing minor histocompatibility antigens (mHags) in patients treated with donor …